New York State Common Retirement Fund Grows Stock Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

New York State Common Retirement Fund increased its holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 713.3% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,200 shares of the company’s stock after buying an additional 10,700 shares during the period. New York State Common Retirement Fund’s holdings in Aquestive Therapeutics were worth $43,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Creative Planning raised its stake in Aquestive Therapeutics by 39.3% in the 3rd quarter. Creative Planning now owns 92,822 shares of the company’s stock valued at $462,000 after purchasing an additional 26,185 shares during the last quarter. Janney Montgomery Scott LLC raised its stake in Aquestive Therapeutics by 4.9% in the 3rd quarter. Janney Montgomery Scott LLC now owns 923,285 shares of the company’s stock valued at $4,598,000 after purchasing an additional 42,800 shares during the last quarter. Cahill Wealth Management LLC raised its stake in Aquestive Therapeutics by 20.6% in the 3rd quarter. Cahill Wealth Management LLC now owns 142,941 shares of the company’s stock valued at $712,000 after purchasing an additional 24,380 shares during the last quarter. Chartwell Investment Partners LLC acquired a new position in Aquestive Therapeutics in the 3rd quarter valued at about $535,000. Finally, GSA Capital Partners LLP raised its stake in Aquestive Therapeutics by 525.5% in the 3rd quarter. GSA Capital Partners LLP now owns 137,151 shares of the company’s stock valued at $683,000 after purchasing an additional 115,223 shares during the last quarter. 32.45% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts recently weighed in on AQST shares. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a research note on Friday, December 20th. Cantor Fitzgerald began coverage on shares of Aquestive Therapeutics in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $17.00 target price for the company. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Aquestive Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $11.00.

Aquestive Therapeutics Price Performance

NASDAQ AQST opened at $2.58 on Friday. Aquestive Therapeutics, Inc. has a 12 month low of $2.24 and a 12 month high of $6.23. The company has a 50-day moving average of $3.11 and a 200-day moving average of $4.12. The company has a market cap of $235.24 million, a P/E ratio of -5.73 and a beta of 2.76.

Aquestive Therapeutics (NASDAQ:AQST) last posted its earnings results on Wednesday, March 5th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). The company had revenue of $11.87 million for the quarter, compared to analysts’ expectations of $13.11 million. As a group, equities research analysts anticipate that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current year.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.